drugset
drugset / Trial / NCT06093308

A Study in Elderly Chinese Subjects With Underlying Diseases

NCT06093308 ↗

Phase 1 Completed 18 enrolled Shanghai Vinnerna Biosciences Co., Ltd. Sponsor GmbH · collab
NaSingle-groupOpen-labelOther

Summary

Evaluate the safety and tolerability of oral JT001 tablets in elderly subjects with underlying diseases. Evaluate the pharmacokinetic characteristics of JT001 tablets orally administered to elderly subjects with underlying diseases. Explore the drug drug interactions between JT001 tablets and some drugs in elderly subjects with underlying diseases who have been orally administered multiple times.

Timeline

Start
2023-07-12
Primary completion
2023-08-25
Completion
2023-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject REMIDEVIR Small molecule 0.3 g Oral

Indications

No indication recorded.